Login to My NLA Account

WARM UP FOR THE NLA’S PENTATHLON CHALLENGE 

Article By:

0
No votes yet

Lipoprotein(a) [Lp(a)] is an independent risk factor for atherosclerotic cardiovascular disease (ASCVD). Although approximately 20% of the population has elevated Lp(a) levels (≥ 50 mg/dL or 125 nmol/L), there are currently no approved targeted medical treatments available. Lp(a) has a unique structure, similar to low-density lipoprotein-cholesterol, with an additional apolipoprotein(a) component, evolved from plasminogen.

Article By:

Rishi Rikhi, MD

T32 Cardiovascular Medicine Fellow
Atrium Health Wake Forest Baptist 
Winston-Salem, NC

Harpreet Bhatia, MD, MAS, FACC

Assistant Professor of Medicine
Division of Cardiovascular Medicine
University of California San Diego
San Diego, CA

0
No votes yet

Happy New Year to All! On behalf of co-editor Dr. Kaye-Eileen Willard and myself, I wish to thank those of you who have contributed to the outstanding issues of LipidSpin during the last year and look forward to the education and clinical insights provided by NLA members in 2023. I’m excited about the articles of this issue, centered on the theme Pushing Boundaries.

Article By:

Lynne T. Braun, PhD, CLS, FNLA*

LipidSpin Co-Editor, National Lipid Association
Chicago, IL

0
No votes yet

Hello fellow NLA members, Happy New Year! I hope everyone had a restful and happy holiday season. I look forward to celebrating the many incredible projects the NLA is executing in 2023, one being this SWLA/PLA LipidSpin. I hope you walk away after reading this with inspiration in your heart and new, helpful lipid science in your pocket.

Article By:

Kevin C. Maki, PhD, CLS, FNLA*

President, National Lipid Association 
Bonita Springs, FL

 

0
No votes yet
Last Updated: Thursday, 09-Feb-2023 15:15:00 EST

 

 

LEVERAGING IMPLEMENTATION SCIENCE 

Last Updated: Monday, 17-Oct-2022 13:00:00 EDT

Are you excited for a new year with the NLA? While we still have so much to accomplish in 2022, there is a lot of excitement about what we will be doing as we head into 2023. The NLA has developed a series of educational activities and engagement opportunities for our members and those interested in lipid management near and far, and we cannot wait for you to take advantage of all the offerings! Here are some of the plans for 2023:

Journal of Clinical Lipidology Editor-in-Chief

The National Lipid Association has started its search for the next Editor-in-Chief for the Journal of Clinical Lipidology. Applications are due by November 1, 2023. Interested candidates must use the following form to indicate your interest in the position. Interviews will be conducted by the NLA Executive Committee and the current Editor-in-Chief, John R. Guyton, MD, FNLA. The Editor-in-Chief will be approved by the NLA Board of Directors.

More information
  • Files must be less than 2 MB.
  • Allowed file types: pdf doc docx.
More information
  • Files must be less than 2 MB.
  • Allowed file types: pdf doc docx.

This page was last updated: Oct 26, 2022

Last Updated: Friday, 09-Sep-2022 21:00:00 EDT

Statin-associated muscle symptoms (SAMS) are the most common form of statin intolerance and are associated with increased risk of cardiovascular events that manifest from statin underutilization and discontinuation. 

Introduction                            

Article By:

Mohini Aras, MD

Assistant Professor of Clinical Medicine, Division of Diabetes, Endocrinology, and Metabolism

Weill Cornell Medical College

New York, NY

Beverly G. Tchang, MD

Assistant Professor of Clinical Medicine, Division of Diabetes, Endocrinology, and Metabolism

Weill Cornell Medical College

New York, NY

Louis J. Aronne, MD

Sanford I. Weill Professor of Metabolic Research, Division of Endocrinology, Diabetes & Metabolism

Weill Cornell Medical College 

New York, NY

0
No votes yet
Last Updated: Thursday, 25-Aug-2022 20:00:00 EDT

Jacksonville, Florida - (August 25, 2022) - The American College of Cardiology (ACC) announced the release of the 2022 ACC Expert Consensus Decision Pathway on the Role of Nonstatin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk: A Report of the American College of Cardiology Solution Set Oversight Committee. The new Expert Consensus Decision Pathway provides practical guidance for lowering LDL-C with nonstatin therapies.